维普中文期刊产品整合服务

One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherpay

查看全文 作　　者：Liang-Ping Xia1,2, Pei-Hong Wu1,3, Jian-Chuan Xia1,4, Bei Zhang1,2, Zhong-Zhen Guan1,5, De-Sen Wan1,6, Gui-Fang Guo1,2, Yi-Xin Zeng1,7 1 State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China;2 VIP Region, Sun Yat-sen Universty Cancer Center, Guangzhou, Guangdong 510060, P. R. China;3 Department of Medical Imaging and Interventional Radiology, Sun Yat-sen Universty Cancer Center, Guangzhou, Guangdong 510060, P. R. China;4 Biotherapy Cancer, Sun Yat-sen Universty Cancer Center, Guangzhou, Guangdong 510060, P. R. China;5 Department of Medical Oncology, Sun Yat-sen Universty Cancer Center, Guangzhou, Guangdong 510060, P. R. China;6 Department of Colorectal Cancer,Sun Yat-sen Universty Cancer Center, Guangzhou, Guangdong 510060, P. R. China;7 Sun Yat-sen Universty Cancer Center, Guangzhou, Guangdong 510060, P. R. China 高影响力作者 出　　处：《Chinese Journal of Cancer》索引2010年第29卷第12期,共6页高影响力期刊 基　　金：Major Sci-Tech Project of 'National Significant New Drug Creation'(No 2008ZX09312-002) 摘　　要：Either cetuximab or bevacizumab can improve the survival of patients with metastastic colorectal cancer (mCRC) if administered combided with cytotoxic agents. However, the effect of two or more target agents in combination is uncertain in these patients. Here, we reported a patient with mCRC successfully treated by a combination of target agents after the failure of chemotherapy. The patient received palliative resection of primary tumor followed by 9 cycles of postoperative XELOX regimen, cytokine-induced killer cell (CIK)-based biotherapy, traditional Chinese medicine, particle implantation in the lung metastatic lesions. The tumor progressed 20 months after the standard treatments. Then, the regimen cetuximab, bevacizumab and cefitinib was applied. During the treatment with targeted agents, grade IV acne-like rash and relatively severe parionychia of the toes occurred. Both of them recovered smoothly. The PET-CT reexamination at 40 days after the target treatment showed that the metabolism of mediastinal lymph nodes basically recovered to a normal level. The combination of multiple targeted agents obtained a progression-free survival(PFS) of 11 months and the patient with a good quality of life during this period. 关 键 词：药物治疗 结直肠癌 转移性 患者 大肠 细胞毒性 靶向药物 不确定性
相关文献

参考文献(30)

引证文献(3)

耦合文献(12)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费